Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?
作者信息
Khan Sujoy
机构信息
Immunology and Allergy, Queen's Centre, Castle Hill Hospital, Cottingham, England.
出版信息
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
Abstract
摘要
相似文献
1
Comment on: Gudu T, Stober C, Cope AP et al. Baricitinib set to join the Covid-19 therapeutic arsenal?
Rheumatology (Oxford). 2021 Oct 2;60(10):e371. doi: 10.1093/rheumatology/keab386.
2
Baricitinib set to join the Covid-19 therapeutic arsenal?
Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
3
Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al.
Clin Infect Dis. 2021 Dec 6;73(11):e3980-e3981. doi: 10.1093/cid/ciaa1210.
4
Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy?
Clin Infect Dis. 2021 Dec 6;73(11):e3978-e3979. doi: 10.1093/cid/ciaa1208.
5
Baricitinib: the first immunomodulatory treatment to reduce COVID-19 mortality in a placebo-controlled trial.
Lancet Respir Med. 2021 Dec;9(12):1349-1351. doi: 10.1016/S2213-2600(21)00358-1. Epub 2021 Sep 1.
6
Use of Baricitinib in Patients With Moderate to Severe Coronavirus Disease 2019.
Clin Infect Dis. 2021 Apr 8;72(7):1247-1250. doi: 10.1093/cid/ciaa879.
7
Baricitinib as Treatment for Coronavirus Disease 2019 (COVID-19): Friend or Foe of the Pancreas?
Clin Infect Dis. 2021 Dec 6;73(11):e3977-e3978. doi: 10.1093/cid/ciaa1209.
8
Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled.
N Engl J Med. 2021 Mar 4;384(9):867-869. doi: 10.1056/NEJMe2034982.
9
Reply to letter to the editor: baricitinib and toxicity is a rare occurrence.
Expert Opin Drug Saf. 2020 Oct;19(10):1371-1372. doi: 10.1080/14740338.2020.1812192. Epub 2020 Aug 24.
10
In patients with COVID-19 receiving IMV or ECMO, adding baricitinib to usual care reduced all-cause mortality.
Ann Intern Med. 2022 Jun;175(6):JC64. doi: 10.7326/J22-0033. Epub 2022 Jun 7.
本文引用的文献
1
Baricitinib set to join the Covid-19 therapeutic arsenal?
Rheumatology (Oxford). 2021 Apr 6;60(4):1585-1587. doi: 10.1093/rheumatology/keab061.
2
Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.
N Engl J Med. 2021 Mar 4;384(9):795-807. doi: 10.1056/NEJMoa2031994. Epub 2020 Dec 11.
3
Janus Family kinase (JAK) inhibitors in HLH and severe COVID-19.
Am J Hematol. 2020 Dec;95(12):1448-1451. doi: 10.1002/ajh.25985. Epub 2020 Sep 30.
4
Limited role for bronchoalveolar lavage to exclude COVID-19 after negative upper respiratory tract swabs: a multicentre study.
Eur Respir J. 2020 Oct 8;56(4). doi: 10.1183/13993003.01733-2020. Print 2020 Oct.
5
Managing high clinical suspicion COVID-19 inpatients with negative RT-PCR: a pragmatic and limited role for thoracic CT.
Thorax. 2020 Jul;75(7):537-538. doi: 10.1136/thoraxjnl-2020-214916. Epub 2020 Apr 21.
Zotero 插件